NCT00855894 - A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Pertuzumab

After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).

DRUG

Erlotinib

Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.

Trial Locations (10)

Sydney

East Melbourne

Heidelberg

Herston

Chermside

Adelaide

Omaha

Los Angeles

Rancho Mirage

Seattle